X4 Pharmaceuticals, Inc XFOR
We take great care to ensure that the data presented and summarized in this overview for X4 Pharmaceuticals, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XFOR
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$16.9 Million3.55% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$15 Million1.46% of portfolio
-
Black Rock Inc. New York, NY8.74MShares$8.74 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.83MShares$7.83 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$7.13 Million0.22% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.58MShares$4.58 Million0.52% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.28MShares$4.28 Million0.01% of portfolio
-
Sio Capital Management, LLC New York, NY3.59MShares$3.59 Million1.61% of portfolio
-
Perceptive Advisors LLC New York, NY3.55MShares$3.55 Million0.1% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY3.47MShares$3.47 Million0.58% of portfolio
Latest Institutional Activity in XFOR
Top Purchases
Top Sells
About XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Insider Transactions at XFOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2024
|
Michael S Wyzga Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+27.0%
|
-
|
|
Jun 10
2024
|
Alison Frances Lawton Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Keith Woods Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+25.0%
|
-
|
|
Jun 10
2024
|
Gary Bridger Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Murray Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+19.03%
|
-
|
|
Jun 10
2024
|
David W J Mcgirr Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Francoise De Craecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Mar 11
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52,500
-100.0%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
49,678
-6.1%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,235
-5.73%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,409
-5.02%
|
$0
$0.88 P/Share
|
|
Feb 12
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
787
-0.32%
|
$787
$1.01 P/Share
|
|
Feb 12
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,683
-1.18%
|
$3,683
$1.01 P/Share
|
|
Feb 12
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
21,695
-2.59%
|
$21,695
$1.01 P/Share
|
|
Feb 12
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,721
-34.56%
|
$27,721
$1.01 P/Share
|
|
Nov 03
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
39,906
-4.55%
|
$0
$0.9 P/Share
|
|
Nov 01
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
199,531
-18.55%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,257
-29.35%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,695
-17.88%
|
$0
$0.73 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.25M shares |
|---|---|
| Open market or private purchase | 25K shares |
| Open market or private sale | 963K shares |
|---|